In normal condition, the heart obtains more than two-thirds of the energy from oxidative metabolism of the long chain fatty acids, although a wide variety of substrates such as glucose, lactate, keton bodies and aminoacids are also utilized. In ischemic myocardium, on the other hand, oxidative metabolism of free fatty acid is suppressed and anaerobic glucose metabolism play a major role for residual oxidative metabolism. Therefore, metabolic imaging can be an important technique for the assessment of various cardiac diseases and conditions. In SPECT, up to the present, several iodinated fatty acid traces have been introduced and studied. Of these, I-123 labeled 15-(p-iodophenyl)3R, S-methylpentadecanoic acid (BMIPP) has been the most commonly used tracers in clinical studies, especially in some of the European countries and Japan. In this review article the 1 characterization of the several fatty acid tracers for SPECT are described and basic and clinical utility of BMIPP are further discussed.
IntroductionThe cardiac muscle metabolizes a variety of substrates by selecting appropriate ones available in the particular myocardial condition. In normal condition, fatty acids and glucose are the most preferred substrate for energy production, followed by lactate, amino acids, keton bodies. Approximately two-thirds or more of the total energy produced by myocardium is derived from fatty acid oxidation and the most of the remaining energy is covered by the glucose metabolism. Both fatty acid and glucose are catabolized to acetyl-COA through beta-oxidation and glycolysis and the metabolite is oxidized in the tricarboxylic acid (TCA) cycle. In various pathological conditions the myocardial metabolism can be changed significantly, for instance, in ischemia, oxidative metabolism of free fatty acid is decreased because ß-oxidation of fatty acid in mitochondria requires a large amount of oxygen, and glucose becomes the preferred substrate for anaerobic glycolysis that requires less oxygen consumption [1,2]. Therefore, imaging tracers that permit direct assessment of myocardial metabolism are desired to evaluate the pathophysiological changes in various heart disease. Current available tracers for metabolic imaging are several fatty acid tracers, 18 F-FDG for the evaluation of glucose metabolism, and 11 C-acetate for the